Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Cited by (1,002)

Items 401–500 of 1,002

1. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
   Shaji Kunnathu Kumar, Thomas Elmer Witzig, Angela A. Dispenzieri, Martha Q. Lacy, Linda E. Wellik, Rafaël Fonseca, John Anthony Lust, Morie Abraham Gertz, Robert A. Kyle, Philip R. Greipp et al. · 2004 · Leukemia
2. Synthesis and antiinflammatory activity of 4-amino-2-aryl-5-cyano-6-{3- and 4-(N-phthalimidophenyl)} pyrimidines
   Emerson Peter da Silva Falcão, Sebastiao Jose de Melo, Rajendra M. Srivastava, Maria Tereza Jansen de A. Catanho, Silène Carneiro do Nascimento · 2006 · European Journal of Medicinal Chemistry
3. Neurologic complications of cancer therapy
   Scott Randall Plotkin, Patrick Yung Wen · 2003 · Neurologic Clinics
4. Intravenous Formulations of the Enantiomers of Thalidomide: Pharmacokinetic and Initial Pharmacodynamic Characterization in Man
   Tommy Eriksson, Sven Erik Björkman, Bodil Roth, Peter Höglund · 2000 · Journal of Pharmacy and Pharmacology
5. Cytokines and signal transduction
   Teru Hideshima, Klaus Podar, Dharminder Chauhan, Kenneth Carl Anderson · 2005 · Best Practice & Research Clinical Haematology
6. Dynamic contrast‐enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology and clinical markers
   S. Nosas-Garcia, Thomas M. Moehler, K. Wasser, Fabian M. Kiessling, Reiner Bartl, IVAN ZUNA, Jens Hillengaß, Hartmut Goldschmidt, Hans‐Ulrich Kauczor, Stefan Delorme · 2005 · Journal of Magnetic Resonance Imaging
7. Advances in Biology and Therapy of Multiple Myeloma
   Sophie Barillé‐Nion, Bart Barlogie, Régis Bataille, Peter Leif Bergsagel, Joshua Epstein, Robert G. Fenton, Joth L. Jacobson, W. Michael Kuehl, John D. Shaughnessy, Guido J. K. Tricot · 2003 · Hematology
8. Efficacy and safety of thalidomide in patients with acute myeloid leukemia
   Martin B. Steins, Teresa Padró, Ralf Bieker, Sandra Ruiz, Martin H. Kropff, Joachim Kienast, Torsten Keßler, Thomas Büchner, Wolfgang E. Berdel, Rolf Michael Mesters · 2002 · Blood
9. Anti-angiogenic agents
   G. Deplanque, Adrian Llewellyn Harris · 2000 · European Journal of Cancer
10. Repurposing drugs to treat cardiovascular disease in the era of precision medicine
    Abdelsayed, Mena, Kort, Eric J., Jovinge, Stefan, Mercola, Mark · 2022 · Nature Reviews Cardiology
11. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
    Sonia Missiroli, Mariasole Perrone, Caterina Boncompagni, Chiara Borghi, Alberto Campagnaro, Francesco Marchetti, Gabriele Anania, Pantaleo Greco, Francesco Fiorica, Paolo Pinton et al. · 2021 · Cancers
12. Thalidomide in the management of multiple myeloma
    Bart Barlogie, Maurizio Zangari, Trey Spencer, Athanasios Fassas, Elias J. Anaissie, A. Badros, Jeana Cromer, Guido J. K. Tricot · 2001 · Seminars in Hematology
13. Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy
    Robert Phillip Baughman, Michael C. Iannuzzi · 2003 · BioDrugs
14. Turning liabilities into opportunities: Off-target based drug repurposing in cancer
    Vinayak C. Palve, Yi Liao, Lily L. Remsing Rix, Uwe Rix · 2020 · Seminars in Cancer Biology
15. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma
    Tsuyoshi Iwasaki, Teruaki Hamano, Atsushi Ogata, Naoaki Hashimoto, Masayasu Kitano, Eizo Kakishita · 2002 · British Journal of Haematology
16. Thalidomide in patients with malignant pleural mesothelioma
    Paul Baas, Willem J. Boogerd, Otilia Dalesio, A. Haringhuizen, Frank L. J. Custers, Nico van Zandwijk · 2004 · Lung Cancer
17. Pomalidomide
    Martha Q. Lacy, Arleigh B. Robertson McCurdy · 2013 · Blood
18. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
    Heinz Ludwig, Meral Beksaç, Joan Bladé, Mario Boccadoro, Jamie D. Cavenagh, Michèle Cavo, Meletios Athanasios Dimopoulos, Johannes W. Drach, Hermann Einsele, Thierry T.F. Facon et al. · 2010 · The Oncologist
19. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy
    Vikram Shaw, Suyash Srivastava, Sanjay K. Srivastava · 2019 · Seminars in Cancer Biology
20. New drugs are not enough‑drug repositioning in oncology: An update
    Armando, Romina, Mengual G�mez, Diego, Gomez, Daniel · 2020 · International Journal of Oncology
21. Hematogenous Dissemination in Corpus Cancer
    Andrea Mariani, Maurice J. Webb, Gary L. Keeney, Giliola Calori, Karl C. Podratz · 2001 · Gynecologic Oncology
22. Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies
    Giovanni Barosi, Michelle Ann Elliott, Letizia Canepa, Filippo Ballerini, Pier Paolo Piccaluga, Giuseppe Visani, Monia Marchetti, Gabriele Pozzato, Francesca Zorat, Ayalew Tefferi · 2002 · Leukemia & lymphoma/Leukemia and lymphoma
23. Bradycardia during therapy for multiple myeloma with thalidomide
    Ibrahim E. Fahdi, Venkat Gaddam, Jorge Felix Saucedo, C. V. Kishan, Keyur S. Vyas, Matthew G. Deneke, Hani A. Razek, Brett T. Thorn, Joseph K. Bissett, Elias Anaisse et al. · 2004 · The American Journal of Cardiology
24. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
    Donald Scott McMeekin, Michael W. Sill, Doris M. Benbrook, Kathleen M. Darcy, Deborah J. Stearns-Kurosawa, Lynne A. Eaton, S. Diane Yamada · 2007 · Gynecologic Oncology
25. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
    Furihata, Hirotake, Yamanaka, Satoshi, Honda, Toshiaki, Miyauchi, Yumiko, Asano, Atsuko, Shibata, Norio, Tanokura, Masaru, Sawasaki, Tatsuya, Miyakawa, Takuya · 2020 · Nature Communications
26. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
    Enrique M. Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San‐Segundo, David Vilanova, Lucía López‐Corral, Juan Carlos Montero, Teresa Hernández‐Iglesias et al. · 2008 · Blood
27. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity
    Dianne D. Pulte, Maria Theresa Redaniel, Hermann Brenner, Lina Jansen, Mona Jeffreys · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
28. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry
    Adrián Macías Alegre, A Granda, Martínez Chamorro, C, Díaz Mediavilla, J, Rafael Martínez, García Laraña, J, Juan José Lahuerta, Anna Maria Sureda, Joan Bladé, Javier de la Rubia et al. · 2002 · PubMed
29. Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma
    David Dingli, Grzegorz S. Nowakowski, Angela A. Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Mark Robert Litzow, Dennis A. Gastineau, Morie Abraham Gertz · 2006 · Clinical Lymphoma & Myeloma
30. Bone Marrow with Diffuse Tumor Infiltration in Patients with Lymphoproliferative Diseases: Dynamic Gadolinium-enhanced MR Imaging
    Alain Rahmouni, Jean‐Luc Montazel, Marine Diviné, Éric Lepage, Karim Belhadj, Philippe Gaulard, Mohamed Bouanane, M. Golli, Hicham Kobeiter · 2003 · Radiology
31. Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
    William Douglas Figg, Erwin A. Kruger, Douglas K. Price, Sonia Kim, William Dahut · 2002 · Investigational New Drugs
32. Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases
    Vinayak Vittal, Mikaela D. Stewart, Peter S. Brzović, Rachel E. Klevit · 2015 · Journal of Biological Chemistry
33. Old wine in new bottles: Drug repurposing in oncology
    Michał Antoszczak, Anna Markowska, Janina Markowska, Adam Huczyński · 2019 · European Journal of Pharmacology
34. Molecular Mechanisms of the Teratogenic Effects of Thalidomide
    Tomoko Asatsuma‐Okumura, Takumi Ito, Hiroshi Handa · 2020 · Pharmaceuticals
35. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
    Suzanne Lentzsch, Michael S. Rogers, Richard LeBlanc, Amy E. Birsner, Jamshed H. Shah, Anthony M. Treston, Kenneth Carl Anderson, Robert J. D’Amato · 2002 · PubMed
36. Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
    Shmuel Yaccoby, Angela Pennisi, X Li, Stacey R. Dillon, Fenghuang Zhan, Bart Barlogie, John D. Shaughnessy · 2007 · Leukemia
37. The malignant clone and the bone-marrow environment
    Klaus Podar, Paul Gerard Guy Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth Carl Anderson · 2007 · Best Practice & Research Clinical Haematology
38. Clinical Significance of Angiogenesis in Gastrointestinal Cancers
    Ronnie T. P. Poon, Sheung-Tat Fan, John Wong · 2003 · Annals of Surgery
39. Novel therapeutic approaches for multiple myeloma
    Teru Hideshima, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2003 · Immunological Reviews
40. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
    Francesco Bertolini, Lisa Fusetti, Patrizia Mancuso, Alberto Gobbi, Chiara Antonia Corsini, Pier Francesco Ferrucci, Giovanni Martinelli, Giancarlo Pruneri · 2000 · Blood
41. Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
    Constantine S. Mitsiades, Nicholas Mitsiades, Paul Gerard Guy Richardson, Nikhil C. Munshi, Kenneth Carl Anderson · 2007 · Journal of Cellular Biochemistry
42. Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma
    Chiun Hsu, Chiung‐Nien Chen, Li‐Tzong Chen, Chenyao Wu, Pei‐Ming Yang, Ming–Yang Lai, Po‐Huang Lee, Ann‐Lii Cheng · 2003 · Oncology
43. Thalidomide: Mechanisms of Action
    Taraneh Paravar, Delphine J. Lee · 2008 · International Reviews of Immunology
44. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
    Ola Landgren · 2013 · Hematology
45. A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations
    Lev Litichevskiy, Ryan Peckner, Jennifer G. Abelin, Jacob K. Asiedu, Amanda L. Creech, John F. Davis, Desiree Davison, Caitlin M. Dunning, Jarrett D. Egertson, Shawn B. Egri et al. · 2018 · Cell Systems
46. Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
    Shaji Kunnathu Kumar, Thomas Elmer Witzig, S. Vincent Rajkumar · 2004 · Journal of Clinical Oncology
47. Promising therapies in multiple myeloma
    Giada Bianchi, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2015 · Blood
48. Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
    Umang Swami, Sanjay Goel, Sridhar Mani · 2013 · Current Drug Targets
49. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues
    Satoshi Yamanaka, Yuto Horiuchi, Saya Matsuoka, Kohki Kido, Kohei Nishino, Mayaka Maeno, Norio Shibata, Hidetaka Kosako, Tatsuya Sawasaki · 2022 · Nature Communications
50. Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
    Shuang Ying Zhou, Fengfei Wang, Tze-Chen Hsieh, JOSEPH M. WU, Erxi Wu · 2013 · Current Medicinal Chemistry
51. Drug repurposing for the treatment of glioblastoma multiforme
    Claudia Abbruzzese, Silvia Matteoni, Michele Signore, Luca Cardone, Kavindra Nath, Jerry D. Glickson, Marco Giorgio Paggi · 2017 · Journal of Experimental & Clinical Cancer Research
52. Thalomid?? (Thalidomide) Capsules
    Todd E. Clark, Norma Edom, Janice Larson, Laura J. Lindsey · 2001 · Drug Safety
53. Clinical implications of angiogenesis in cancers
    Roberta W. C. Pang, Ronnie T. P. Poon · 2006 · Vascular Health and Risk Management
54. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia
    E. Harris, Judith Behrens, D Samson, Amin Rahemtulla, Nigel H. Russell, Jenny Byrne · 2003 · British Journal of Haematology
55. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
    Marco Ladetto, Sonia Vallet, Andreas Trojan, Maria Dell'Aquila, Luigia Monitillo, Rosalba Rosato, Loredana Santo, Daniela Drandi, Alessandra Bertola, Patrizia Falco et al. · 2005 · Blood
56. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
    Ito, Takumi, Handa, Hiroshi · 2016 · International Journal of Hematology
57. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
    Farhat Latif Khanim, Blair Merrick, Hannah Victoria Giles, Monika Jankute, J. BARRY JACKSON, LJ Giles, Jane Birtwistle, Christopher M. Bunce, Mark Trehane Drayson · 2011 · Blood Cancer Journal
58. Thalidomide and its derivatives: emerging from the wilderness
    JN Gordon, Patrick M. Goggin · 2003 · Postgraduate Medical Journal
59. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond
    Rohit Moudgil, Edward T.H. Yeh · 2016 · Canadian Journal of Cardiology
60. Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib
    Klaus Podar, Reshma Shringarpure, Yu‐Tzu Tai, Melissa Simoncini, Martin Sattler, Kenji Ishitsuka, Paul Gerard Guy Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth Carl Anderson · 2004 · Cancer Research
61. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Badros, Ashraf Z, Siegel, Eric, Bodenner, Donald, Zangari, Maurizio, Zeldis, Jerome, Barlogie, Bart, Tricot, Guido · 2002 · The American Journal of Medicine
62. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
    Liu, Jiye, Song, Tianyu, Zhou, Wenrong, Xing, Lijie, Wang, Su, Ho, Matthew, Peng, Zhengang, Tai, Yu-Tzu, Hideshima, Teru, Anderson, Kenneth C. et al. · 2019 · Leukemia
63. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma
    Prahlad V. Raninga, Giovanna Di Trapani, Slavica Vučković, Maneet Bhatia, Kathryn Fay Tonissen · 2015 · Oncotarget
64. Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
    Constantine S. Mitsiades, Faith E. Davies, Jacob P. Laubach, Douglas Joshua, Jesús F. San Miguel, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2011 · Journal of Clinical Oncology
65. Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy.
    Fiorella Guadagni, Patrizia Ferroni, Raffaele Palmirotta, Ilaria Portarena, Vincenzo Formica, Mario Roselli · 2007 · PubMed
66. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    Seema Singhal, R Powles, Bhawna Sirohi, J Treleaven, S Kulkarni, Jayesh Mehta · 2002 · Bone Marrow Transplantation
67. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Klaus Podar, Laurence P. Catley, Yu‐Tzu Tai, Reshma Shringarpure, Pedro Carvalho, Toshiaki Hayashi, Renate Burger, Robert L Schlossman, Paul Gerard Guy Richardson, Lini N. Pandite et al. · 2003 · Blood
68. TARGETING TUMOUR NECROSIS FACTOR ALPHA
    Jeffrey R. LaDuca, Anthony A. Gaspari · 2001 · Dermatologic Clinics
69. ‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factors
    Sophia Danhof, Martin Schreder, Leo Rasche, Susanne Strifler, Hermann Einsele, Stefan Tobias Knop · 2015 · European Journal Of Haematology
70. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
    Frank M. Cichocki, Ryan Bjordahl, Jodie P. Goodridge, Sajid Mahmood, Svetlana Gaidarova, Ramzey Abujarour, Zachary Davis, Aimee Marie Merino, Katie Tuininga, Hongbo Wang et al. · 2022 · Nature Communications
71. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-α in an animal model of inflamed Alzheimer’s disease brain
    Jae Kyu Ryu, James G. McLarnon · 2007 · Neurobiology of Disease
72. Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features
    Athanasios Fassas, Susan M. Ward, Firas Muwalla, Rudy L. Van Hemert, Keith Oliver Schluterman, Sami I. Harik, Guido J. K. Tricot · 2003 · Leukemia & lymphoma/Leukemia and lymphoma
73. Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas
    Susan C Short, Daphne Traish, Anna Dowe, Frances Hines, Martin Eric Gore, Michael Brada · 2001 · Journal of Neuro-Oncology
74. Thalidomide neuropathy in patients treated for metastatic prostate cancer
    Fiona M. Molloy, Mary Kay Floeter, Nadir Ali Syed, Friedhelm Sandbrink, E. Culcea, Seth M. Steinberg, William L. Dahut, James M. Pluda, Erwin A. Kruger, E Reed et al. · 2001 · Muscle & Nerve
75. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
    Wolfram Pönisch, Marta J. Rozanski, Hartmut Goldschmidt, Franz Albert Hoffmann, Thomas Boldt, Andreas Schwarzer, Ute Ritter, Robert Rohrberg, Elke Schwalbe, Jens Uhlig et al. · 2008 · British Journal of Haematology
76. Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
    Francesca F. Patriarca, Hermann Einsele, Francesco Spina, Benedetto Bruno, Miriam Isola, Chiara Nozzoli, Andrea Nozza, Alessandra A. Sperotto, Fortunato Morabito, Gernot Stuhler et al. · 2011 · Transplantation and Cellular Therapy
77. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
    Alicia J. Angelbello, Jonathan L. Chen, Jessica L. Childs‐Disney, Peiyuan Zhang, Zi-Fu Wang, Matthew David Disney · 2018 · Chemical Reviews
78. Thalidomide-associated deep vein thrombosis and pulmonary embolism
    Charles L. Bennett, Glen T. Schumock, Apurva A. Desai, Hau C. Kwaan, Dennis W. Raisch, Rebecca C. Newlin, Walter Michael Stadler · 2002 · The American Journal of Medicine
79. Multiple Myeloma
    Jean‐Luc Harousseau, John D. Shaughnessy, Paul Gerard Guy Richardson · 2004 · Hematology
80. The thin red line
    Francesco Bertolini, Patrizia Mancuso, Alberto Gobbi, Giancarlo Pruneri · 2000 · Experimental Hematology
81. Emerging biologics in inflammatory bowel disease
    Heyson Chi-hey Chan, Siew C. Ng · 2016 · Journal of Gastroenterology
82. Inflammasome inhibitors: promising therapeutic approaches against cancer
    Shengchao Xu, Xizhe Li, Yuanqi Liu, Yu Xia, Ruimin Chang, Chunfang Zhang · 2019 · Journal of Hematology & Oncology
83. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    P. Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Alexandra J. Croockewit, Gregor E. G. Verhoef, Jan J. Cornelissen, Martijn R. Schaafsma, Marinus H. J. van Oers, Pierre Wijermans et al. · 2007 · Haematologica
84. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio‐geo‐demographic factors in the era of novel agents
    Mohammed Al‐Hamadani, Shahrukh Khurshid Hashmi, Ronald S. Go · 2014 · American Journal of Hematology
85. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
    Albert Y. Lin, Nathalie A. Brophy, George Albert Fisher, Sam K.S. So, Christopher A. Biggs, Torunn Ingrid Yock, Lee Levitt · 2004 · Cancer
86. Current role of thalidomide in cancer treatment
    Deborah Ann Thomas, Hagop M. Kantarjian · 2000 · Current Opinion in Oncology
87. Thalidomide in Cancer
    Seema Singhal, Jayesh Mehta · 2001 · BioDrugs
88. The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    Jacob P. Laubach, Anuj Kumar Mahindra, Constantine S. Mitsiades, R. L. Schlossman, Nikhil C. Munshi, Irene M. Ghobrial, Nicole A. Carreau, Teru Hideshima, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2009 · Leukemia
89. Recent advances in the molecular mechanism of thalidomide teratogenicity
    Gao, Shaobing, Wang, Shichao, Fan, Ruihua, Hu, Jieying · 2020 · Biomedicine & Pharmacotherapy
90. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
    Giovanni Barosi, Mario Boccadoro, Michèle Cavo, Paolo Corradini, Monia Marchetti, Massimo Massaia, Giampaolo Merlini, Patrizia Tosi, Sante Tura · 2004 · PubMed
91. BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia
    Morton Coleman, John Paul Leonard, Larry Lyons, Karen A. Pekle, Kenneth Nahum, Roger Niles Pearse, Rubén Niesvizky, Joseph Michaeli · 2002 · Leukemia & lymphoma/Leukemia and lymphoma
92. Molecular mechanisms of cereblon-based drugs
    Tomoko Asatsuma‐Okumura, Takumi Ito, Hiroshi Handa · 2019 · Pharmacology & Therapeutics
93. Angiogenesis: A Target for Cancer Therapy
    Giampaolo Tortora, Davide Melisi, Fortunato Ciardiello · 2004 · Current Pharmaceutical Design
94. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
    Noopur S Raje, Teru Hideshima, Faith E. Davies, Dharminder Chauhan, Steven Peter Treon, Gloria Q. Young, Yu‐Tzu Tai, David Avigan, Jianlin Gong, Robert L Schlossman et al. · 2004 · British Journal of Haematology
95. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
    JoséM. Hernández, Ramón García‐Sánz, E. Golvano, Joan Bladé, Javier Fernández‐Calvo, J. Trujillo, Alfons Soler, Santiago Gardella, F. Carbonell, G. Mateo et al. · 2004 · British Journal of Haematology
96. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Massimo Offidani, Laura Corvatta, Monica Marconi, Giuseppe Visani, Francesco Alesiani, Marino Brunori, Piero Galieni, Massimo Catarini, Maurizio Burattini, Riccardo Centurioni et al. · 2006 · PubMed
97. Thalidomide in multiple myeloma: current status and future prospects
    Jamie D. Cavenagh, Heather E. Oakervee, on behalf of the UK Myeloma Forum and The BCSH Haematology/Oncology Task Forces · 2002 · British Journal of Haematology
98. New investigational drugs with single-agent activity in multiple myeloma
    Archana M. Rajan, Shaji Kunnathu Kumar · 2016 · Blood Cancer Journal
99. Discovering discovery patterns with predication-based Semantic Indexing
    Trevor Cohen, Dominic Widdows, Roger W. Schvaneveldt, Peter Davies, Thomas C. Rindflesch · 2012 · Journal of Biomedical Informatics
100. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome
     Robert Zeiser, Barbara Deschler-Baier, Hartmut Bertz, Jürgen Finke, Monika Martha Engelhardt · 2004 · Bone Marrow Transplantation